Showing 355 graded companies. Showing 4 of them. 242 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Barinthus Biotherapeutics plcBRNS | D- | — | $0.00 | — | -$26.4M | — |
| vTv Therapeutics Inc.VTVT | C- | — | $36.8M | -20.8% | — | — |
| Theravance Biopharma, Inc.TBPH | C | — | $104.3M | 51.6% | $238.5M | — |
| Lunai Bioworks Inc.LNAI | B | — | $52K | -6,852.0% | -$5.3M | — |
351 more biotechnology companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded ADARx Pharmaceuticals, Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
ADRX · ·
$13.25-2.3%Nov 11 close
The latest quarter (ended September 30, 2026) is from ADARx Pharmaceuticals’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once ADARx Pharmaceuticals files it.